FIG. 1



CA19-9 and CEA Biomarkers
CA19-9 (units/mL)
CEA (ng/mL)
1500
1250
1000
750
500
250
0
30
20
10
0
10/31/2018
11/30/2018
12/31/2018
1/31/2019
2/28/2019
CA19-9
CEA

FIG. 2



% Change from Baseline in Sum of Longest Diameters
0
-20
-40
-60
-80
SD 180 mg
SD 180 mg
SD 720 mg
SD 720 mg
PR 960 mg
PR 180 mg
PR 960 mg
PR 960 mg
PR 360 mg
Subjects Receiving Compound A
180 mg
360 mg
720 mg
960 mg

FIG. 3



First Response (PR or better)
PR: 5
Best Overall Response
PR: 5
SD: 4
Disease Progression
2
Ongoing on-study
11
180 mg
360 mg
720 mg
960 mg
Subjects Received Treatment
Duration of Treatment (Weeks)
0
5
10
15
20
25
30
35
40
45
PR
SD

FIG. 4



% Change from Baseline in Sum of Longest Diameters
100
80
60
40
20
0
-20
-40
-60
-80
-100
360 mg PD
720 mg SD
PD 360 mg
360 mg SD
PD 360 mg
360 mg SD
PD 360 mg
180 mg SD
SD 960 mg
360 mg SD
SD 180 mg
180 mg SD
SD 720 mg
720 mg SD
SD 360 mg
Patients Receiving Compound A
180 mg
360 mg
720 mg
960 mg

FIG. 5



Subjects Received Treatment
Duration of Treatment (Weeks)
0
5
10
15
20
25
30
35
40
180 mg
360 mg
720 mg
960 mg
First Response (PR or better) 0
Best Overall Response SD: 14 PD: 3
Disease Progression 6
Ongoing on-study 13
SD
PD

FIG. 6



Planned dose: 180 mg 360 mg
720 mg 960 mg
% Change from Baseline in Sum of Longest Diameter
100
80
60
40
20
0
−20
−40
−60
−80
−100
720 mg
180 mg
960 mg
960 mg
960 mg
960 mg
720 mg
180 mg
960 mg
960 mg
720 mg
960 mg
180 mg
960 mg
720 mg
960 mg
960 mg
360 mg
SD
SD
SD
SD#
SD#
SD#
SD#
SD#
SD#
SD#
PR
PR#
PR#*
PR#
PR*
PR
PR*
PR#
PR#*
PR#
PR#*,a
*Study ongoing
#Confirmed response
Evaluable NSCLC patients with available post-baseline tumor data (N = 22)b

FIG. 7



Planned dose: 180 mg 360 mg
720 mg 960 mg
First Response (PR or better)
Best Overall Response
Disease progression
On study
Death
Patients with PR, N = 11
Median (range) duration of treatment--weeks
15.1 (4.1–42.3)
8/11 patients continuing study
Patients with SD, N = 11
Median (range) duration of treatment--weeks
10.0 (4.1–35.1)
8/11 patients continuing study
Evaluable NSCLC Patients, N = 23
0 5 10 15 20 25 30 35 40 45 50 55
Duration of Treatment (Weeks)

FIG. 8



960 mg
All dose levels
6-mo PFS KM estimate:
• All doses: 20.6%
3-mo PFS KM estimate:
• All doses: 58.5%
• 960 mg: 59.7%
960 mg (N = 25)
All dose levels (N = 42)
Probability
1.00
0.75
0.50
0.25
0.00
0
2
4
6
8
10
Months
Number at risk
All Dose 42 32 18 2 1
960 mg Dose 25 20 12 0 0

FIG. 9



960 mg
All dose levels
6-mo OS KM estimate:
All doses: 76.4%
960 mg: 82.9%
960 mg (N = 25)
All dose levels (N = 42)
Survival probability
1.00
0.75
0.55
0.25
0.00
0 1 2 3 4 5 6 7 8 9 10 11 12
Months
Number of patients at risk
All Dose 42 40 29 19 9 3 0
960 mg 25 25 17 9 6 0

FIG. 10



% Change from Baseline in Sum of Longest Diameters
100
80
60
40
20
0
-20
-40
-60
-80
-100
Planned Dose
180 mg
360 mg
720 mg
960 mg
PD
SD
PR
360 mg
960 mg
180 mg
720 mg

FIG. 11



Dose
180 mg
360 mg
720 mg
960 mg
No. of patients by dose
180 mg (N = 2)
360 mg (N = 10)
720 mg (N = 4)
960 mg (N = 24)
Target Lesion Size % Change from Baseline
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
0
6
12
18
24
30
36
42
48
54
60
Weeks

FIG. 12



Dose
180 mg
360 mg
720 mg
960 mg
No. of patients by dose
180 mg (N = 2)
360 mg (N = 10)
720 mg (N = 4)
960 mg (N = 24)
Target Lesion Size % Change from Baseline
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
0
6
12
18
24
30
36
42
48
54
60
Weeks

FIG. 13



Dose
180 mg
360 mg
720 mg
960 mg
No. of patients by dose
180 mg (N = 2)
360 mg (N = 10)
720 mg (N = 4)
960 mg (N = 24)
Target Lesion Size % Change from Baseline
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
0
6
12
18
24
30
36
42
48
54
60
Weeks

FIG. 14



Dose
180 mg
360 mg
720 mg
960 mg
No. of patients by dose
180 mg (N = 2)
360 mg (N = 10)
720 mg (N = 4)
960 mg (N = 24)
Target Lesion Size % Change from Baseline
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
0
6
12
18
24
30
36
42
48
54
60
Weeks

FIG. 15



Dose
180 mg
360 mg
720 mg
960 mg
No. of patients by dose
180 mg (N = 2)
360 mg (N = 10)
720 mg (N = 4)
960 mg (N = 24)
Target Lesion Size % Change from Baseline
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
0
6
12
18
24
30
36
42
48
54
60
Weeks

FIG. 16



First Response (PR or better)
Best Overall Response
Disease progression
Ongoing treatment
Death
Planned Dose
180 mg
360 mg
720 mg
Subjects Received Treatment
Duration of Treatment (Weeks)
0
10
20
30
40
50
60
SD
PD

FIG. 17



First Response (PR or better)
Best Overall Response
Disease progression
Ongoing treatment
Death
Planned Dose 960 mg
Duration of Treatment (Weeks)
Subjects Received Treatment
0
10
20
30
40
50
60
SD
PD
PR

FIG. 18




% Change from Baseline in Sum of Longest Diameters
100
80
60
40
20
0
−20
−40
−60
−80
−100
Tumor types are denoted by color
Small cell lung cancer
Appendiceal
Bile duct
Endometrial
Pancreatic
Esophageal
Ampullary
Pancreatic
Pancreatic
Small bowel
Sinonasal
Pancreatic
Pancreatic
Pancreatic
Unknown
Appendiceal
Endometrial
Melanoma
PD
SD
SD
SD
PD
SD
PD
SD
SD
PD
SD
SD
SD
SD
SD
PR[b]
PR[b]
PR[b]

FIG. 19


First Response (PR or better)
Best Overall Response
Disease progression
Ongoing treatment
Death
Duration of Treatment (Weeks)
0
10
20
30
40
50
60
Pancreatic
Pancreatic
Pancreatic
Pancreatic
Pancreatic
Pancreatic
Pancreatic
Pancreatic
Appendiceal
Appendiceal
Appendiceal
Appendiceal
Endometrial
Endometrial
Melanoma
Bile duct
Small bowel
Small cell lung
Esophageal
Sinonasal
Ampullary
Unknown
SD
PD
PR